Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?
Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs? JAMA Oncol. 2018 03 01; 4(3):333-334.
View in:
PubMed
subject areas
Humans
Immunologic Factors
Immunotherapy
Neoplasms
authors with profiles
Richard Schilsky